Glycolysis

Why glycolysis matters

• Universal pathway. Glycolysis is found in essentially all living cells — bacteria, archaea, fungi, plants, animals — making it one of the strongest pieces of evidence for shared biochemical ancestry. The 10-step Embden-Meyerhof-Parnas variant is the most common, with minor variants (Entner-Doudoroff in some bacteria) representing the same logic with different intermediates.
• Sole ATP source for several cell types. Mature mammalian red blood cells lack mitochondria and rely entirely on glycolysis for the ~25 mg of glucose per liter per hour they consume. Sprinting fast-twitch muscle and the renal medulla also lean heavily on glycolysis when oxygen demand outstrips supply.
• About 2% efficiency, but ~100x faster than oxphos. Aerobic complete combustion of glucose yields ~32 ATP, so anaerobic glycolysis at 2 ATP captures only about 6 percent of the available energy. But glycolytic flux can be 10–100 times faster than oxidative phosphorylation, which is why high-power-output cells (cancer, sprinting muscle) preferentially use it.
• PFK-1 is the master metabolic switch. Allosteric inhibition by ATP and citrate, activation by AMP and fructose-2,6-bisphosphate, makes PFK-1 the principal point at which insulin, glucagon, and energy state regulate glycolytic throughput. Insulin raises fructose-2,6-bisphosphate via PFK-2, accelerating glycolysis after meals.
• Substrate for biosynthesis. Glycolytic intermediates feed many other pathways. Glucose-6-phosphate enters the pentose phosphate pathway (ribose for nucleotides, NADPH for biosynthesis); dihydroxyacetone phosphate becomes glycerol-3-phosphate for membrane lipids; pyruvate becomes alanine; 3-phosphoglycerate becomes serine. Cancer cells exploit this aggressively — the Warburg effect.
• Oncology imaging marker. FDG-PET imaging uses radioactive 18F-fluorodeoxyglucose, a glucose analog phosphorylated by hexokinase but trapped because PFK-1 cannot process it. Tumors light up because they import glucose at 5–15x normal rates — clinical exploitation of glycolytic upregulation that Warburg first noted a century ago.
• Genetic disorders are diagnostically informative. Pyruvate kinase deficiency causes hereditary hemolytic anemia (~1 in 20,000) because RBCs cannot generate enough ATP. PFK-1 deficiency (Tarui disease) causes exercise intolerance with myoglobinuria. Each disease pinpoints which enzyme is rate-limiting in which tissue.

Common misconceptions

• Glycolysis requires oxygen. No — glycolysis itself is anaerobic; oxygen is needed only downstream if pyruvate is to enter the Krebs cycle. The pathway runs identically with or without oxygen; what differs is what happens to the pyruvate and how NAD+ is regenerated. Yeast under anaerobic conditions ferment pyruvate to ethanol; muscle ferments to lactate.
• Anaerobic glycolysis means no oxygen present. 'Anaerobic glycolysis' usually means glycolysis followed by lactate fermentation, which can occur even when oxygen is present (the Warburg effect). The terminology is confusing — 'aerobic glycolysis' refers to the same 10 steps with downstream lactate production despite oxygen availability.
• The pathway runs once per glucose. Glucose splits at step 4 into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. Triose phosphate isomerase converts DHAP to G3P, so steps 6–10 run twice per starting glucose. That is why payoff-phase ATP and NADH counts are doubled (4 ATP, 2 NADH from 2 G3P molecules).
• Glycolysis is irreversible. Most steps are near-equilibrium and reversible. Three steps are essentially irreversible under cellular conditions: hexokinase (step 1), PFK-1 (step 3), and pyruvate kinase (step 10). Gluconeogenesis bypasses these three with different enzymes (glucose-6-phosphatase, fructose-1,6-bisphosphatase, PEP carboxykinase + pyruvate carboxylase) — making it a separate pathway, not just glycolysis run backward.
• NADH from glycolysis goes straight to the electron transport chain. Cytoplasmic NADH cannot cross the inner mitochondrial membrane directly. It is shuttled in via the malate-aspartate shuttle (yields 2.5 ATP per NADH equivalent) or the glycerol-3-phosphate shuttle (yields 1.5 ATP). The choice depends on tissue — skeletal muscle and brain favor the glycerol-3-phosphate shuttle, liver and kidney favor malate-aspartate.
• The pathway is a recent discovery. Eduard Buchner showed in 1897 that yeast extract — not living cells — could ferment sugar to ethanol, founding biochemistry. The 10-step glycolytic pathway was elucidated over the next 40 years, with major contributions from Embden and Meyerhof in the 1930s. Buchner won the 1907 Nobel; Meyerhof won in 1922 for muscle metabolism.

How glycolysis works

The pathway has two halves. The preparatory phase (steps 1–5) spends 2 ATP to convert one 6-carbon glucose into two 3-carbon glyceraldehyde-3-phosphate molecules. Hexokinase phosphorylates glucose to glucose-6-phosphate (trapping it in the cell, since the membrane cannot pass charged sugars). Phosphoglucose isomerase shuffles the carbonyl from C1 to C2, producing fructose-6-phosphate. PFK-1 phosphorylates again to fructose-1,6-bisphosphate — the committed, regulated step. Aldolase cleaves this symmetric molecule into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, and triose phosphate isomerase interconverts the two so both halves can enter the next phase.

The payoff phase (steps 6–10) earns back 4 ATP and 2 NADH (running twice — once per triose). Glyceraldehyde-3-phosphate dehydrogenase oxidizes G3P to 1,3-bisphosphoglycerate while reducing NAD+ to NADH and incorporating an inorganic phosphate. Phosphoglycerate kinase transfers the high-energy phosphate to ADP, producing the first payoff ATP per triose (so 2 ATP per glucose) — this is substrate-level phosphorylation. Phosphoglycerate mutase shifts the phosphate from C3 to C2; enolase dehydrates the molecule to phosphoenolpyruvate; pyruvate kinase transfers the second high-energy phosphate to ADP, producing the final 2 ATP and pyruvate. Net per glucose: 4 ATP made − 2 ATP spent = 2 ATP; 2 NADH; 2 pyruvate. Pyruvate then either enters mitochondria for oxidation (yielding ~28–30 more ATP downstream) or is reduced to lactate (in muscle, RBCs) or ethanol (in yeast) to regenerate NAD+ so glycolysis can keep running.

Glycolysis vs gluconeogenesis

Property	Glycolysis	Gluconeogenesis
Direction	Glucose → 2 pyruvate	2 pyruvate → glucose
Net ATP cost	Yields 2 ATP + 2 NADH	Costs 6 ATP + 2 NADH per glucose
Location	Cytoplasm of all cells	Cytoplasm + mitochondria of liver and kidney
Key bypass enzymes	Hexokinase, PFK-1, pyruvate kinase	Glucose-6-phosphatase, fructose-1,6-bisphosphatase, PEPCK + pyruvate carboxylase
Hormonal stimulus	Insulin (via fructose-2,6-bisphosphate)	Glucagon, cortisol (lower fructose-2,6-bisphosphate)
Physiologic context	Fed state, exercise	Fasting, prolonged exercise
Substrate sources	Glucose from food, glycogen	Lactate (Cori cycle), alanine, glycerol
Reciprocal regulation	Same intermediates, opposite enzymes	Both cannot run high-flux at once (futile cycle prevention)

Aerobic vs anaerobic glycolysis (Warburg effect)

Feature	Aerobic (full oxidation)	Anaerobic (lactate fermentation)	Aerobic glycolysis (Warburg)
Oxygen present?	Yes	No	Yes
Pyruvate fate	Mitochondrial Krebs cycle + ETC	Lactate (NAD+ regenerated)	Lactate despite O2 availability
ATP per glucose	~30–32	2	2 (plus rapid biosynthesis)
Speed	Slow (~10–100x slower)	Fast	Fast
Cell types	Most resting tissue	RBCs, sprinting muscle, anaerobes	Cancer, activated lymphocytes, embryonic tissue
Lactate output	Negligible	Stoichiometric with glucose	~10x normal tissue rate
Imaging exploit	—	—	FDG-PET tumor detection
First described	—	Pasteur 1860s (yeast)	Otto Warburg 1920s, Nobel 1931

Famous experiments and case studies

• Eduard Buchner 1897 — cell-free fermentation. Buchner, in Tübingen, ground yeast cells with sand and silica, pressed out a clear juice, and showed that this cell-free extract could still ferment sugar to ethanol. The result demolished the prevailing 'vitalist' view that life processes required intact cells and founded the field of biochemistry. Nobel Prize 1907.
• Embden-Meyerhof-Parnas 1930s — pathway elucidation. Gustav Embden in Frankfurt, Otto Meyerhof in Heidelberg, and Jakub Parnas in Lwów (now Lviv, Ukraine) over the 1930s identified the intermediates and enzymes of glycolysis. The pathway is named after all three. Meyerhof had won the 1922 Nobel for the relation between oxygen consumption and lactate in muscle.
• Otto Warburg 1920s — tumor glycolysis. Warburg observed in slices of rat hepatoma and other tumors that lactate output was about 10 times higher than in normal tissue, even when oxygen was abundant. He proposed (incorrectly, as later work showed) that this was due to defective mitochondria. The 'Warburg effect' label survived; the explanation has shifted to biosynthesis demand. Warburg won the 1931 Nobel for the iron-containing nature of the respiratory enzyme cytochrome oxidase.
• Jagendorf 1966 / Mitchell chemiosmosis context. While not strictly a glycolysis experiment, Peter Mitchell's 1961 chemiosmotic hypothesis (Nobel 1978) explained why aerobic complete oxidation yields ~32 ATP whereas glycolysis alone yields 2 — the difference is the proton-motive force across the mitochondrial inner membrane that glycolysis cannot harness on its own.
• Pyruvate kinase deficiency in human RBCs. Patients homozygous for loss-of-function mutations in PKLR (the RBC pyruvate kinase isozyme) develop chronic hemolytic anemia because their RBCs cannot generate enough ATP to maintain Na+/K+ ATPase function and membrane integrity. Affects roughly 1 in 20,000 worldwide; mitapivat (FDA-approved 2022) is a small-molecule activator that restores residual enzyme activity.